2-048 - Maternal perinatal depression and antidepressant exposure: Pathways to infant neurobehavioral dysregulation

Session Type: Paper Symposium

Integrative Statement

Perinatal exposures to maternal depression raise significant concerns about the developing fetus, neonate, and infant, with implications for the later development of psychopathology. Accumulating evidence has identified links between fetal conditions and long-term health and development. In this symposium, three speakers will describe studies that explored associations between perinatal exposures to maternal depression and fetal or infant functioning, all from a developmental psychopathology perspective. The first paper examined the potential roles of prenatal exposure to mothers’ depression and their antidepressant medication in fetal heart rate (FHR), movement, and heart rate-movement ‘coupling.’ The second paper will report on tests of prospective associations between perinatal depressive disorder and maternal circadian cortisol regulation and infant cortisol stress response at days 1 and 30 postpartum. The third paper will describe a study testing a model of the interacting roles of prenatal antidepressants and infant serotonin transporter genotype as moderators of the association between mothers’ perinatal depression and infant temperament at 3-, 6- and 12-months postpartum.
Each study takes advantage of relatively large, prospective, longitudinal designs, with multiple psychometrically sound measures of exposures and fetal or infant functioning. Our discussant, an expert in developmental neuroscience and infant development, will explore implications of these findings for furthering understanding of mediators and moderators of risk for the development of psychopathology of infants exposed to their mothers’ perinatal depression.

Sub Unit

• Biological Processes

Chair

• Sherryl H Goodman, Emory Univ

Discussant

• Tim F Oberlander, Child and Family Research Institute

Individual Presentations

• Child Sex Moderates the Effect of Maternal Psychotropic Medication Use on Fetal Neurobehavioral Development - Presenting Author: Hanna Catharina Gustafsson, Columbia University; Zachary N. Stowe, University of Arkansas for Medical Sciences; D. Jeffrey Newport, The Ohio State University; Lee Seonjoo, Columbia University Medical Center; Tianshu Feng, Columbia University Medical Center; Bettina T. Knight, University of Arkansas for Medical Sciences; Natalie Morris, Columbia University Medical Center; Catherine Monk, Columbia University

• Maternal perinatal depressive disorder: Prenatal programming of maternal and neonatal cortisol (dys)regulation - Presenting Author: Laura R Stroud, Brown Medical School; Margaret H Bublitz, Brown University; Stephanie H Parade, Brown University; Alison J. McCallum, Brown University

• Prenatal antidepressants, perinatal depression, and serotonin transporter genotype interact to predict infant temperament - Presenting Author: Meaghan McCallum, Emory University; Sherryl H Goodman, Emory Univ; Joseph F. Cubells, Emory University; Adriana Lori, Emory University; D. Jeffrey Newport, The Ohio State University; Zachary N. Stowe, University of Arkansas for Medical Sciences